UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
University of California, Davis
Thomas Jefferson University
Alliance for Clinical Trials in Oncology
Masonic Cancer Center, University of Minnesota
Northwestern University
National Cancer Institute (NCI)